Since most luminal BC patients are initially treated with endocrine therapy, we first analyzed the correlation between the response to these therapies (tamoxifen or aromatase inhibitors) and TRIB3 expression in databases from published studies [43]. Here, TRIB3 is linked to breast cancer.